Clinical trials: Chronic Stable Angina
Myocardial Infarction, Percutaneous Transluminal Coronary Angioplasty
Integration of Telemedicine and Home-Based Cardiac Rehabilitation: Feasibility, Efficacy, and Adherence
The aim of this study is to evaluate feasibility, efficacy, and adherence of home-based cardiac rehabilitation with the integration of telemedicine.
- Conditions
- Myocardial Infarction, Percutaneous Transluminal Coronary Angioplasty, Coronary Artery Bypass, Stable Angina
- Trial name
- NCT05972070
- Testing
- ROMTech Portable Connect
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- ROM Technologies, INC
Chronic Stable Angina
Evaluating Dose-proportionality of Dilatrend Suspended-Release Capsule
This study is designed to evaluate dose-proportionality of Dilatrend SR 8mg, 16mg, 32mg, 64mg, 128mg in healthy male volunteers.
- Trial name
- NCT01369472
- Testing
- Dilatrend SR capsule
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Coronary Artery Disease
FAME II - Fractional Flow Reserve (FFR) Guided Percutaneous Coronary Intervention (PCI) Plus Optimal Medical Treatment (OMT) Verses OMT
The overall purpose of the FAME II trial is to compare the clinical outcomes, safety and cost-effectiveness of FFR-guided PCI plus optimal medical treatment (OMT) versus OMT alone in patients with stable coronary artery disease.
- Trial name
- NCT01132495
- Testing
- Stenting plus OMT, OMT, Standard of care
- Where
- 29 sites in United States, Belgium and 11 more
- Volunteers
- 1,170 people
- Sponsor
- Abbott Medical Devices
Angina
Effect of Febuxostat Compared to Placebo on Exercise Tolerance in Participants With Chronic Stable Angina
The purpose of this study is to evaluate the effect of febuxostat, once daily (QD), compared to placebo as an add on to stable anti-anginal therapy, on the total exercise time of participants with Chronic Stable Angina.
- Trial name
- NCT01549977
- Testing
- Febuxostat
- Where
- 21 sites in United States
- Volunteers
- 1 people
- Sponsor
- Takeda
Microvascular Coronary Artery Disease
A Dose Titration Study to Assess the Effects of SAR407899 in Patients With MVA and/or Persistent Stable Angina Despite Angiographically Successful PCI
Primary Objective: To assess the effects of SAR407899 on coronary vasomotor function using the coronary flow reserve (CFR) in participants with microvascular angina (MVA) and/or persistent stable angina despite angiographically…
- Trial name
- NCT03236311
- Testing
- SAR407899, Adenosine, Regadenoson
- Where
- 10 sites in United States, Denmark and 3 more
- Volunteers
- 10 people
- Sponsor
- Sanofi
Stable Angina, Unstable Angina
Pivotal, Single-arm Clinical Trial to Assess the Efficacy and Safety of the MedHub AutocathFFR Software Device
Prospective (analysis of retrospective data), multi-center, observational, single-arm study. This structure was selected as the "worst case" due to the fact that it represents real life usage of invasive FFR measurement is…
- Conditions
- Stable Angina, Unstable Angina, NSTEMI
- Trial name
- AutocathFFR (NCT04861519)
- Testing
- Collecting invasive FFR measurements.
- Where
- 3 sites in Israel
- Volunteers
- 308 people
- Sponsor
- Medhub Ltd.
Stable Angina (SA), NSTE-ACS (NSTEMI and UA)
Utilisation of Angiox® in European Practice
The objective of this study is to determine utilisation patterns in patients receiving Angiox® in participating European centres.
- Conditions
- Stable Angina (SA), NSTE-ACS (NSTEMI and UA), STEMI (STE-ACS)
- Trial name
- EURO-vision (NCT01011504)
- Where
- 2 sites in France, Germany
- Volunteers
- 2,019 people
- Sponsor
- The Medicines Company
Chronic Stable Angina
A Randomized, Open-label, Single-dose, Crossover Clinical Trial to Evaluate the Food Effect on the Pharmacokinetics of Dilatrend SR 64mg Capsule After Oral Administration in Healthy Male Volunteers
A randomized, open-label, single-dose, crossover clinical trial to evaluate the food effect on the pharmacokinetics of Dilatrend SR 64mg capsule after oral administration in healthy male volunteers.
- Trial name
- NCT01340248
- Testing
- Dilatrend 64mg capsule
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Stable Angina, Non-ST-elevation Acute Coronary Syndrome
Japanese Coronary Intervention Using Drug Eluting and Perfusion Therapy for Left Main Disease (JDEPTH-LM Registry)
JDEPTH-LM Registry is a prospective, observational, multi-center study designed for the efficacy and safety of Double-effect kissing balloon technique (W-KBT) in left main (LM) bifurcation percutaneous coronary intervention (PCI)…
- Conditions
- Stable Angina, Non-ST-elevation Acute Coronary Syndrome, Unstable Angina
- Trial name
- NCT06436092
- Where
- 32 sites in Japan
- Volunteers
- 280 people
- Sponsor
- TCROSS Co., Ltd.
Essential Hypertension, Chronic Stable Angina
Study to Compare the Pharmacokinetic Characteristics and Safety of Dilatrend SR Capsule 32mg and Dilatrend Tablet 25mg
The purpose of this study is to compare the pharmacokinetic characteristics and safety of dilatrend SR capsule 32mg and Dilatrend tablet 25mg in healthy male subjects.
- Conditions
- Essential Hypertension, Chronic Stable Angina, Congestive Heart Failure
- Trial name
- NCT01819870
- Testing
- Dilatrend SR capsule 32mg, Dilatrend IR tablet 25mg
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Stable Angina
Safety And Feasibility Study Of Pressure-controlled Intermittent Coronary Sinus Occlusion (PICSO) In Patients With Coronary Artery Disease Undergoing Native Vessel Intervention
Pressure intermittent coronary sinus occlusion (PICSO) in patients with coronary artery disease improves collateral flow index to higher than 30%. PICSO used in this patient population is safe, feasible and effective.
- Trial name
- PICSO (NCT01308125)
- Testing
- PICSO
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- Miracor Medical SA
Hypertension
Clinical Trial to Evaluate Pharmacokinetic Profiles and Safety Between CKD-385 and D935 in Healthy Volunteers
A randomized, open-label, fed, single dose, crossover study to evaluate the pharmacokinetic profiles and safety of CKD-385 in healthy volunteers
- Trial name
- NCT03748212
- Testing
- D935 Cap. 1T, CKD-385 Tab. 1T
- Where
- South Korea
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Stable Angina
Efficacy and Safety of Monocordil Manufactured by Laboratórios Baldacci
Phase III clinical study for the evaluation of clinic and cardiologic effects of isosorbide mononitrate from the incidence of events (angina episodes). This is an open, comparative, monocentric trial.
- Trial name
- NCT02152579
- Testing
- Isosorbide-5-mononitrate
- Where
- Brazil
- Volunteers
- 86 people
- Sponsor
- Laboratórios Baldacci S.A
Angina Pectoris, Coronary Artery Disease
Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina
This study will evaluate the effect of ranolazine compared to placebo on the average weekly angina frequency in subjects with chronic stable angina and coronary artery disease (CAD) who have a history of type 2 diabetes mellitus…
- Conditions
- Angina Pectoris, Coronary Artery Disease, Type 2 Diabetes Mellitus
- Trial name
- TERISA (NCT01425359)
- Testing
- Ranolazine
- Where
- 135 sites in United States, Belarus and 12 more
- Volunteers
- 949 people
- Sponsor
- Gilead Sciences
Stable Angina Pectoris
Extended-Release RANCAD in the Patients With Stable Angina Pectoris
A double-blind, randomized, placebo-controlled, parallel study to evaluate the effects of add-on RANCAD on exercise tolerance and angina frequency in patients with stable angina pectoris.
- Trial name
- NCT02294942
- Testing
- RANCAD
- Where
- 6 sites in Taiwan
- Volunteers
- 75 people
- Sponsor
- TSH Biopharm Corporation Limited
Angina Pectoris, Angina Pectoris, Stable
REDUCER-I: An Observational Study of the Neovasc Reducer™ System
The purpose of this study is to collect long term data of the Reducer System in subjects with refractory angina pectoris.
- Conditions
- Angina Pectoris, Angina Pectoris, Stable, Chronic Stable Angina
- Trial name
- NCT02710435
- Testing
- Reducer System
- Where
- 25 sites in Austria, Belgium and 7 more
- Volunteers
- 400 people
- Sponsor
- Shockwave Medical, Inc.
Essential Hypertension, Chronic Stable Angina
Observational Study to Evaluate the Safety of DILATREND SR Cap. in Korean Patients With Essential Hypertension, Chronic Stable Angina and Congestive Heart Failure
The purpose of this study is to Evaluate the Safety of DILATREND SR Cap. in Korean Patients with Essential hypertension, Chronic stable angina and Congestive heart failure for 52 weeks.
- Conditions
- Essential Hypertension, Chronic Stable Angina, Congestive Heart Failure
- Trial name
- DELIGHT (NCT03063697)
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Angina Pectoris
Angiogenesis in Women With Angina Pectoris Who Are Not Candidates for Revascularization
The purpose of this study is to determine whether a one-time intracoronary infusion of Ad5FGF-4 is effective in reducing the time to onset myocardial ischemia as measured by exercise treadmill testing and improving myocardial…
- Trial name
- AWARE (NCT00438867)
- Testing
- Ad5FGF-4
- Where
- 47 sites in United States
- Volunteers
- 300 people
- Sponsor
- Cardium Therapeutics
Stable Angina
Treadmill Cardiovascular Safety Study of Erenumab (AMG 334)
A phase 2a, multicenter, randomized, double-blind, placebo-controlled study in adults with stable angina to evaluate the effect of erenumab (AMG 334) compared to placebo on exercise time during an exercise treadmill test.
- Trial name
- NCT02575833
- Testing
- Erenumab
- Where
- 33 sites in United States, Bulgaria and 8 more
- Volunteers
- 89 people
- Sponsor
- Amgen
Angina Pectoris
Phase III Trial of Dantonic® (T89) Capsule to Prevent and Treat Stable Angina
This phase III study is designed as a double blind, randomized, multi-nation, multi-center, placebo controlled clinical research, which aims to evaluate the safety and efficacy of Dantonic® (T89) in patients with chronic stable…
- Trial name
- CAESA (NCT01659580)
- Testing
- T89 high dose, T89 Low dose, Sanqi+Bingpian
- Where
- 94 sites in United States, Belarus and 5 more
- Volunteers
- 1,004 people
- Sponsor
- Tasly Pharmaceuticals, Inc.